Continuity Biosciences Expands into Aesthetic Drug Delivery with PinPrint Investment
Continuity Biosciences, LLC has made a notable strategic investment in PinPrint, Inc., a pioneering company known for its cutting-edge 3D-printed microneedle technology aimed at revolutionizing drug delivery. This investment marks an important expansion for Continuity, broadening its scope beyond therapeutic interventions to include aesthetic and cosmetic applications.
Founded by renowned chemist and inventor Dr. Joseph DeSimone, PinPrint has brought forth a transformative platform that prevents the over-hardening of resin within negative spaces, enabling the construction of highly precise microchannels essential for biomedical applications like microneedle patches and microfluidic devices. Dr. DeSimone's groundbreaking work as the Sanjiv Sam Gambhir Professor of Translational Medicine and Chemical Engineering at Stanford University shines a light on the advanced methodologies employed by PinPrint to maximize efficiency and patient comfort.
The primary innovation that arises from PinPrint is a next-generation microneedle patch, which has been designed to facilitate the intradermal delivery of vaccines and therapeutics. This innovative technology has the potential to replace traditional injections, thereby redefining the patient experience in therapeutic and cosmetic domains. Dr. DeSimone emphasized, "By integrating high-resolution 3D printing with advanced drug delivery mechanisms, we are setting a new standard for precision and comfort in the administration of treatments."
The strategic investment aligns perfectly with Continuity's mission of fostering precise drug delivery technologies. Currently, the company is engaged in a collaboration with the Grattoni Laboratory at the Houston Methodist Hospital to develop implanted nanofluidic platforms that allow for prolonged drug delivery. As highlighted by Ramakrishna Venugopalan, PhD, co-founder and CEO of Continuity Biosciences, "This investment opens pathways for us to diversify our offering from implanted nanofluidic systems to an external microfluidic platform that can enhance direct delivery of dermatological and aesthetic substances into the dermis."
Moreover, as part of the investment transaction, Dr. Venugopalan will join the Board of Directors at PinPrint. Renee Ryan, MBA, co-founder and CEO of PinPrint, stated, "We are excited to welcome Krishna to our board. His expertise and strategic leadership will be crucial as we redefine drug and vaccine delivery mechanisms."
Continuity Biosciences, LLC is dedicated to advancing drug delivery technologies aimed at addressing chronic and complex diseases. Headquartered in Bradenton, Florida, with a branch in Houston, Texas, the company focuses on enhancing the precision and effectiveness of therapeutic delivery. For more information, visit www.continuitybiosciences.com.
PinPrint, Inc. is at the forefront of transforming drug and vaccine delivery through innovative 3D-printed microneedle platforms, aiming to improve outcomes and patient comfort across both therapeutic and aesthetic applications.
Understand the profound implications this partnership holds for the future of drug delivery systems, as it combines pioneering technology with industry expertise to cater to evolving patient needs.
Founded by renowned chemist and inventor Dr. Joseph DeSimone, PinPrint has brought forth a transformative platform that prevents the over-hardening of resin within negative spaces, enabling the construction of highly precise microchannels essential for biomedical applications like microneedle patches and microfluidic devices. Dr. DeSimone's groundbreaking work as the Sanjiv Sam Gambhir Professor of Translational Medicine and Chemical Engineering at Stanford University shines a light on the advanced methodologies employed by PinPrint to maximize efficiency and patient comfort.
The primary innovation that arises from PinPrint is a next-generation microneedle patch, which has been designed to facilitate the intradermal delivery of vaccines and therapeutics. This innovative technology has the potential to replace traditional injections, thereby redefining the patient experience in therapeutic and cosmetic domains. Dr. DeSimone emphasized, "By integrating high-resolution 3D printing with advanced drug delivery mechanisms, we are setting a new standard for precision and comfort in the administration of treatments."
The strategic investment aligns perfectly with Continuity's mission of fostering precise drug delivery technologies. Currently, the company is engaged in a collaboration with the Grattoni Laboratory at the Houston Methodist Hospital to develop implanted nanofluidic platforms that allow for prolonged drug delivery. As highlighted by Ramakrishna Venugopalan, PhD, co-founder and CEO of Continuity Biosciences, "This investment opens pathways for us to diversify our offering from implanted nanofluidic systems to an external microfluidic platform that can enhance direct delivery of dermatological and aesthetic substances into the dermis."
Moreover, as part of the investment transaction, Dr. Venugopalan will join the Board of Directors at PinPrint. Renee Ryan, MBA, co-founder and CEO of PinPrint, stated, "We are excited to welcome Krishna to our board. His expertise and strategic leadership will be crucial as we redefine drug and vaccine delivery mechanisms."
About Continuity Biosciences
Continuity Biosciences, LLC is dedicated to advancing drug delivery technologies aimed at addressing chronic and complex diseases. Headquartered in Bradenton, Florida, with a branch in Houston, Texas, the company focuses on enhancing the precision and effectiveness of therapeutic delivery. For more information, visit www.continuitybiosciences.com.
About PinPrint, Inc.
PinPrint, Inc. is at the forefront of transforming drug and vaccine delivery through innovative 3D-printed microneedle platforms, aiming to improve outcomes and patient comfort across both therapeutic and aesthetic applications.
Understand the profound implications this partnership holds for the future of drug delivery systems, as it combines pioneering technology with industry expertise to cater to evolving patient needs.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.